- Home
- PMAX vs LTRN Comparison
PMAX vs LTRN Comparison
Compare PMAX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMAX | LTRN |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 46.8M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PMAX | LTRN |
|---|---|---|
| Price | $1.65 | $2.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 185.9K | 81.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.11 |
| 52 Week High | $5.20 | $4.86 |
Technical Indicators
Market Signals| Indicator | PMAX | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 43.78 |
| Support Level | $1.49 | $2.49 |
| Resistance Level | $1.88 | $3.67 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 42.22 | 69.05 |
Price Performance
Historical ComparisonAbout PMAX Powell Max Limited
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.